Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
| Autor: | Nathalie Laplace, Pierre-Emmanuel Bonnot, Matthieu Siebert, Mohammad Alyami, Guillaume Passot, Laurent Villeneuve, Naoual Bakrin, Olivier Glehen, Frederic Mercier, Vahan Kepenekian |
|---|---|
| Přispěvatelé: | Ciblage thérapeutique en Oncologie (EA3738), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Peritoneal metastasis Exploratory laparotomy [SDV]Life Sciences [q-bio] medicine.medical_treatment Hyperthermic Intraperitoneal Chemotherapy 03 medical and health sciences 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Adverse effect Peritoneal Neoplasms Aged Retrospective Studies Aerosols Chemotherapy business.industry Nebulizers and Vaporizers Cytoreduction Surgical Procedures General Medicine Middle Aged medicine.disease Combined Modality Therapy 3. Good health Surgery Oxaliplatin Oncology Doxorubicin 030220 oncology & carcinogenesis Conventional PCI Peritoneal mesothelioma Female 030211 gastroenterology & hepatology Hyperthermic intraperitoneal chemotherapy Cisplatin business Cytoreductive surgery |
| Zdroj: | EJSO-European Journal of Surgical Oncology EJSO-European Journal of Surgical Oncology, WB Saunders, 2021, 47, pp.128-133. ⟨10.1016/j.ejso.2019.06.028⟩ |
| ISSN: | 0748-7983 |
| DOI: | 10.1016/j.ejso.2019.06.028 |
| Popis: | Background PIPAC is a recent method of intraperitoneal chemotherapy. The aim of this study was to describe the clinical characteristics of the patients who became amenable to CRS & HIPEC after PIPAC treatment. Methods All patients diagnosed with unresectable PM who became resectable throughout PIPAC treatment were included. Outcome criteria were adverse events following PIPAC procedure and rate of secondary CRS and HIPEC. Results Four hundred thirty-seven PIPAC were done in 146 consecutive patients. Among them, 26 patients (17.8%) who underwent 76 PIPAC were scheduled for CRS and HIPEC after reduction of the peritoneal burden. PM were from gastric, peritoneal mesothelioma, ovarian, colorectal and small bowel in 13, 7, 4, 1 and 1 patients, respectively. At the time of the first PIPAC, median age was 58.6 years (32–76.3). Median PCI was 16 (1–39). All patients had systemic chemotherapy in between PIPAC session. Median consecutive PIPAC procedure was 3 (1–8). Complications occurred in 3 PIPAC session (4%) and there was no major complication (CTCAE III or higher). Complete CRS and HIPEC was achieved in 21 patients of the 26 scheduled (14.4%). The remaining 5 patients were considered unresectable at the exploratory laparotomy. Among patients who underwent CRS and HIPEC, with median follow-up of 7 (1–26) months, 14 patients (66.7%) were alive without recurrence, 2 patients (9.5%) were alive with recurrence and 5 patients (23.8%) died. Conclusions Complete CRS and HIPEC can be achieved in strictly selected patient with unresectable PM at diagnosis after repeated PIPAC session with palliative intent. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect